GET IN TOUCH
Brochure

Your Fast Track to IND

Rapid, Robust, Reliable Cell Line Development using Aragen’s CHOMaxTM Platform with Fut∞KO

Accelerate Speed to Clinic with Productivity, Precision & Confidence

Introducing Aragen’s CHOMax™ platform with Fut∞KO—engineered for speed, precision, and maximum productivity. It features a glycoengineered GS KO cell line that supports full afucosylation, resulting in enhanced ADCC and improved therapeutic potency.

The Aragen Advantage

  1. Speed: Rapid generation of RCB in 16 weeks
  2. Track Record: 200+ programs completed successfully
  3. Royalty-Free: CHO-GS and CHO-DG44 platforms
  4. Regulatory Acceptance: Strong global presence of the platform with more than 110 licenses signed worldwide and over 86 accepted regulatory filings
  5. TnT Transposon Technology: Enables e icient and highly stable gene integration
  6. High Productivity: Minimum titers of 4 g/L for most mAbs and BsAbs, with titers up to 25 g/L post-intensification
  7. Scalability: Excellent scalability across various bioreactor formats
  8. Comprehensive Support and Documentation: Full traceability and detailed cell line history pack Regulatory Acceptance

Cell line Development Expertise

A Robust and Flexible CHO Expression Platform

RCB generation in CHOMax™ Platform with Fut∞KO in ~11-12 weeks.

Our platform is consistently reviewed by global regulatory authorities, delivering industry-leading titers, streamlined processes, and comprehensive IND/BLA-ready documentation. From grams to kilograms in scale, Aragen reliably supports therapeutic CLD, diagnostic reagents, high-throughput screening, and critical bioanalytical requirements.

× img

Contact An Expert Today!